epocrates logo
epocrates logo
epocrates logo
  • 0

Diseases

Evaluation of hyperkalemia

OVERVIEW

  • Summary
  • Urgent Considerations
  • Etiology

DIAGNOSIS

  • Differential Diagnosis
  • Diagnostic Approach

IMAGES

  • Library

REFERENCES

  • Citations
  • Credits

Summary

AAFont SizeShareMore Information
Hyperkalemia is defined as significant when the serum potassium value >6.0 mEq/L (>6.0 mmol/L). Moderate hyperkalemia is defined as serum potassium values in the 5.0 to 6.0 mEq/L (5.0 to 6.0 mmol/L) range. Small changes in serum potassium values can have significant muscular and cardiac effects when significant hyperkalemia is present.
Hyperkalemia is most commonly due either to high intake of potassium in the setting of decreased renal excretion or to extracellular redistribution of potassium from intracellular locations. There is a limited correlation between an elevated serum potassium value and an excess in total body potassium stores. Clinical manifestations of hyperkalemia are uncommon with values <6.0 mEq/L (<6.0 mmol/L).
Common acute manifestations of significant hyperkalemia include muscle weakness and ECG changes, with the latter having the potential to progress to a life-threatening arrhythmia.[1]​​ Significant hyperkalemia represents a medical emergency, and an ECG should be obtained to establish whether cardiotoxicity is present. Continuous ECG monitoring should occur until serum potassium values have been brought into a safe range and cardiotoxicity has resolved.
Whereas the treatment of significant hyperkalemia is pre-emptive in the patient without electrocardiographic change, in the presence of electrocardiographic change significant hyperkalemia represents a true medical emergency and requires rapid implementation of measures to reduce serum potassium concentration.
ECG changes in patients with hyperkalemia
ECG changes in patients with hyperkalemia
BMJ 2009; 339:b4114. Copyright ©2009 by the BMJ Publishing Group
content by BMJ Group
Last updated

Library

  • ECG changes in patients with hyperkalemia

    ECG changes in patients with hyperkalemia

Citations

    Key Articles

    • Lott C, Truhlář A, Alfonzo A, et al. European Resuscitation Council guidelines 2021: cardiac arrest in special circumstances. Resuscitation. 2021 Apr;161:152-219.[Abstract][Full Text]

    • Panchal AR, Bartos JA, Cabañas JG, et al. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020 Oct 20;142(16_suppl_2):S366-468.[Abstract][Full Text]

    • Deakin C, Soar J, Davies R. Resuscitation Council UK. Special circumstances guidelines. May 2021 [internet publication].[Full Text]

    • Rafique Z, Peacock F, Armstead T, et al. Hyperkalemia management in the emergency department: an expert panel consensus. J Am Coll Emerg Physicians Open. 2021 Oct 1;2(5):e12572.[Abstract][Full Text]

    • Rossignol P, Legrand M, Kosiborod M, et al. Emergency management of severe hyperkalemia: guideline for best practice and opportunities for the future. Pharmacol Res. 2016 Nov;113(pt a):585-91.[Abstract]

    Referenced Articles

    • 1. Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med. 2000 Oct;18(6):721-9.[Abstract]

    • 2. Chan R, Sealey JE, Michelis MF, et al. Renin-aldosterone system can respond to furosemide in patients with hyperkalemic hyporeninism. J Lab Clin Med. 1998;132:229-235.[Abstract]

    • 3. Palmer BF, Clegg DJ. Hyperkalemia across the continuum of kidney function. Clin J Am Soc Nephrol. 2018 Jan 6;13(1):155-7.[Abstract][Full Text]

    • 4. Tamarisa KP, Aaronson KD, Koelling TM. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J. 2004;148:971-978.[Abstract]

    • 5. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int. 1993;44:643-653.[Abstract]

    • 6. Kim S, Joo KW. Electrolyte and acid-base disturbances associated with non-steroidal anti-inflammatory drugs. Electrolyte Blood Press. 2007 Dec;5(2):116-25.[Abstract][Full Text]

    • 7. Velazquez H, Perazella MA, Wright FS, et al. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 1993;119:296-301.[Abstract]

    • 8. Lachaal M, Venuto RC. Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine. Am J Med. 1989;87:260-263.[Abstract]

    • 9. Memoli E, Faré PB, Camozzi P, et al. Trimethoprim-associated electrolyte and acid-base abnormalities. Minerva Med. 2021 Aug;112(4):500-5.[Abstract][Full Text]

    • 10. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004 Aug 5;351(6):585-92.[Abstract]

    • 11. Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 2000;58:2084-2092.[Abstract][Full Text]

    • 12. Venzin RM, Cohen CD, Maggiorini M, et al. Aliskiren-associated acute renal failure with hyperkalemia. Clin Nephrol. 2009;98:326-328.[Abstract]

    • 13. Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med. 1995;71:575-586.[Abstract]

    • 14. Bengalorkar GM, Sarala N, Venkatrathnamma PN, et al. Effect of heparin and low-molecular weight heparin on serum potassium and sodium levels. J Pharmacol Pharmacother. 2011 Oct;2(4):266-9.[Abstract][Full Text]

    • 15. Pei Y, Richardson R, Greenwood C, et al. Extrarenal effect of cyclosporine A on potassium homeostasis in renal transplant recipients. Am J Kidney Dis. 1993;22:314-319.[Abstract]

    • 16. Lee CH, Kim GH. Electrolyte and acid-base disturbances induced by clacineurin [sic] inhibitors. Electrolyte Blood Press. 2007 Dec;5(2):126-30.[Abstract][Full Text]

    • 17. Bushinsky DA, Gennari FJ. Life-threatening hyperkalemia induced by arginine. Ann Intern Med. 1978;89:632-634.[Abstract]

    • 18. Seto A, Murakami M, Fukuyama H, et al. Ventricular tachycardia caused by hyperkalemia after administration of hypertonic mannitol. Anesthesiology. 2000;93:1359-1361.[Abstract]

    • 19. Gennari FJ. Hypokalemia. N Engl J Med. 1998;339:451-458.[Abstract]

    • 20. Sica DA. Antihypertensive therapy and its effects on potassium homeostasis. J Clin Hypertens (Greenwich). 2006 Jan;8(1):67-73.[Abstract]

    • 21. Borron SW, Bismuth C, Muszynski J. Advances in the management of digoxin toxicity in the older patient. Drugs Aging. 1997;10:18-33.[Abstract]

    • 22. Gronert GA. Cardiac arrest after succinylcholine: Mortality greater with rhabdomyolysis than receptor upregulation. Anesthesiology. 2001;94:523-529.[Abstract]

    • 23. Ochoa-Gomez J, Villar-Arias A, Aresti I, et al. A case of severe hyperkalaemia and compartment syndrome due to rhabdomyolysis after drugs abuse. Resuscitation. 2002;54:103-105.[Abstract]

    • 24. Kalemkerian GP, Darwish B, Varterasian ML. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med. 1997;103:363-367.[Abstract]

    • 25. Colussi G, Cipriani D. Pseudohyperkalemia in extreme leukocytosis. Am J Nephrol. 1995;15:450-452.[Abstract]

    • 26. Graber M, Subramani K, Corish D, et al. Thrombocytosis elevates serum potassium. Am J Kidney Dis. 1988;12:116-120.[Abstract]

    • 27. Saperstein DS. Muscle channelopathies. Semin Neurol. 2008;28:260-269.[Abstract]

    • 28. Lott C, Truhlář A, Alfonzo A, et al. European Resuscitation Council guidelines 2021: cardiac arrest in special circumstances. Resuscitation. 2021 Apr;161:152-219.[Abstract][Full Text]

    • 29. Panchal AR, Bartos JA, Cabañas JG, et al. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020 Oct 20;142(16_suppl_2):S366-468.[Abstract][Full Text]

    • 30. Deakin C, Soar J, Davies R. Resuscitation Council UK. Special circumstances guidelines. May 2021 [internet publication].[Full Text]

    • 31. Rafique Z, Peacock F, Armstead T, et al. Hyperkalemia management in the emergency department: an expert panel consensus. J Am Coll Emerg Physicians Open. 2021 Oct 1;2(5):e12572.[Abstract][Full Text]

    • 32. Rossignol P, Legrand M, Kosiborod M, et al. Emergency management of severe hyperkalemia: guideline for best practice and opportunities for the future. Pharmacol Res. 2016 Nov;113(pt a):585-91.[Abstract]

    • 33. Lavonas EJ, Akpunonu PD, Arens AM, et al. 2023 American Heart Association focused update on the management of patients with cardiac arrest or life-threatening toxicity due to poisoning: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2023 Oct 17;148(16):e149-84.[Abstract][Full Text]

    • 34. Batterink J, Cessford TA, Taylor RA. Pharmacological interventions for the acute management of hyperkalaemia in adults. Cochrane Database Syst Rev. 2015 Oct 29;10(10):CD010344.[Abstract][Full Text]

    • 35. Cheng CJ, Chiu JS, Huang WH, et al. Acute hyperkalemic paralysis in a uremic patient. J Nephrol. 2005;18:630-633.[Abstract]

    • 36. Medicine and Healthcare products Regulatory Agency. National patient safety alert: potential risk of underdosing with calcium gluconate in severe hyperkalaemia (NatPSA/2023/007/MHRA). Jun 2023 [internet publication].​[Full Text]

    • 37. UK Kidney Association. Treatment of acute hyperkalaemia in adults. 2023 [internet publication].[Full Text]

    • 38. Choi MJ, Ziyadeh FN. The utility of the transtubular potassium gradient in the evaluation of hyperkalemia. J Am Soc Nephrol. 2008;19:424-426.[Abstract][Full Text]

    • 39. Kidney Disease: Improving Global Outcomes (KDIGO). Acute kidney injury (AKI)​. Mar 2012 [internet publication].[Full Text]

    • 40. Statland JM, Fontaine B, Hanna MG, et al. Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve. 2018 Apr;57(4):522-30.[Abstract][Full Text]

    • 41. Wasserman K, Stringer WW, Casaburi R, et al. Mechanism of the exercise hyperkalemia: an alternate hypothesis. J Appl Physiol 1997;83:631-643.[Abstract][Full Text]

    • 42. Clausen T. Quantification of Na+,K+ pumps and their transport rate in skeletal muscle: functional significance. J Gen Physiol. 2013 Oct;142(4):327-45.[Abstract][Full Text]

Have feedback?
Tell us about your experience
Scroll to Top
epocrates logo

Sign in to access our clinical decision support tools

Sign inCreate Account
Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & Feedback
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information